Ephrin B2 (EFNB2) is a transmembrane ligand for the Eph family of receptor tyrosine kinases. It plays crucial roles in neural development, synaptic plasticity, neurovascular coupling, and has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. EFNB2 is unique among ephrin ligands in its ability to signal bidirectionally—forward signaling through Eph receptors and reverse signaling through its cytoplasmic domain.
Gene Symbol
EFNB2
Alias
EFN-B2, LERK5, EPLG5
Full Name
Ephrin B2
Chromosome
13q33.3
NCBI Gene ID
[1948](https://www.ncbi.nlm.nih.gov/gene/1948)
OMIM
[600530](https://www.omim.org/entry/600530)
Ensembl ID
[ENSG00000145088](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145088)
UniProt ID
[P52799](https://www.uniprot.org/uniprotkb/P52799/entry)
Protein Length
333 amino acids
Molecular Weight
~38 kDa
The ephrin family consists of:
- Ephrin A ligands (EFNA1-5) — GPI-anchored
- Ephrin B ligands (EFNB1-3) — transmembrane
EFNB2 belongs to the ephrin-B subfamily and is one of the most studied ephrin ligands due to its critical roles in development and disease.
¶ Protein Structure and Biochemistry
¶ Extracellular Domain
The extracellular domain of EFNB2 contains:
- Receptor-binding domain — interacts with Eph receptors
- Conserved cysteine-rich region — maintains structural integrity
- Cleavage site — can be proteolytically processed
- Single pass transmembrane helix
- Mediates cell-cell contact-dependent signaling
¶ Intracellular (Cytoplasmic) Domain
The cytoplasmic tail contains:
- PDZ domain-binding motif — engages PDZ domain proteins
- Tyrosine residues — can be phosphorylated for signaling
- C-terminal intracellular tail — enables reverse signaling
A unique feature of ephrin-B ligands is their ability to signal in both directions:
- Forward signaling — EFNB2 activates Eph receptor on adjacent cell
- Reverse signaling — EFNB2 cytoplasmic domain transduces signals into the EFNB2-expressing cell
During development, EFNB2 shows dynamic expression patterns:
- Vascular system — arterial specification
- Nervous system — axon guidance, segmentation
- Mesenchymal tissues — boundary formation
In the adult brain, EFNB2 is expressed in:
- Neurons — dendritic shafts, synaptic compartments
- Astrocytes — astrocytic endfeet
- Endothelial cells — blood-brain barrier
- Oligodendrocyte precursor cells — white matter
Axon Guidance
EFNB2 is a critical guidance cue for developing axons. During development:
- Corpus callosum formation — EFNB2/EphB signaling guides callosal axons
- Retinotectal mapping — topographic mapping via ephrin gradients
- Spinal cord development — commissural axon guidance
Drescher et al. (2002) established that EFNB2 provides repulsive guidance signals for retinal ganglion cell axons.
Cortical Development
Fischer et al. (2016) demonstrated EFNB2's role in:
- Cortical neuron migration
- Dendrite morphogenesis
- Layer formation
Synapse Formation
During development, EFNB2/EphB interactions initiate:
- Presynaptic differentiation
- Postsynaptic assembly
- Synaptic contact formation
LTP and LTD
EFNB2 signaling modulates synaptic plasticity:
- Long-term potentiation (LTP) — EFNB2 enhances LTP through EphB receptor activation
- Long-term depression (LTD) — reverse signaling contributes to LTD mechanisms
Ethell et al. (2001) showed that EFNB2 function is required for synaptic plasticity in vivo.
Synaptic Structure
The ephrin/Eph system regulates:
- Dendritic spine morphology
- Synaptic protein clustering
- PSD formation and organization
EFNB2 plays a crucial role in:
- Blood-brain barrier (BBB) maintenance — see: Blood-brain barrier
- Angiogenesis — blood vessel formation and patterning
- Neurovascular unit — signaling between neurons, glia, and vasculature
Zhang et al. (2022) demonstrated EFNB2's critical role in BBB integrity.
EFNB2 mediates:
- Forward signaling — through Eph receptors on neighboring cells
- Reverse signaling — through its cytoplasmic domain
- Dendrite-dendrite interactions — in dendritic tiling
EFNB2 is prominently implicated in AD pathogenesis through multiple mechanisms:
Synaptic Dysfunction
Synaptic dysfunction is an early feature of AD. EFNB2 contributes by:
- Altering EphB receptor signaling in synapses
- Affecting AMPA and NMDA receptor function
- Disrupting spine morphology
Chen et al. (2018) reviewed the role of ephrin signaling in neurodegenerative diseases, highlighting EFNB2's involvement in AD.
Amyloid Pathology
Liu et al. (2019) demonstrated:
- EFNB2 expression is altered in AD brain
- Ephrin/Eph signaling interacts with APP processing
- Amyloid-beta affects ephrin expression
Tau Pathology
- EFNB2 phosphorylation is altered in tauopathy
- Interactions with tau phosphorylation pathways
- May affect tau spreading
Blood-Brain Barrier Dysfunction
- EFNB2 is critical for BBB integrity
- BBB breakdown is an early AD feature
- EFNB2/EphB4 signaling maintains endothelial function
Shen et al. (2020) showed EFNB2's involvement in neuroinflammation and AD pathogenesis.
Vascular Contributions
- EFNB2 regulates cerebral blood flow
- Alters neurovascular coupling in AD
- Contributes to vascular amyloid deposition
In Parkinson's disease, EFNB2 plays roles in:
Dopaminergic Neuron Function
- EFNB2/EphB signaling affects dopaminergic neuron development
- Altered expression in PD substantia nigra
- May affect neuron vulnerability
Xu et al. (2021) demonstrated ephrin involvement in dopaminergic neuron vulnerability.
α-Synuclein Pathogenesis
- Potential interactions with alpha-synuclein
- May affect Lewy body formation
- Synaptic dysfunction mechanisms
- Amyotrophic Lateral Sclerosis (ALS) — motor neuron expression
- Huntington's Disease — altered in disease models
- Multiple Sclerosis — demyelination and remyelination
When EFNB2 binds to Eph receptors (mainly EphB2, EphB3, EphB4), it triggers:
- Receptor dimerization — Eph receptors cluster upon ligand binding
- Tyrosine phosphorylation — auto-phosphorylation activates kinase domain
- Downstream signaling — recruitment of adaptor proteins
Key Pathways Activated:
- Rho GTPase pathways — RhoA, Rac, Cdc42
- PI3K/Akt pathway — cell survival and growth
- MAPK/ERK pathway — gene expression and plasticity
- FAK pathway — cytoskeletal organization
The cytoplasmic domain of EFNB2 transduces signals through:
- PDZ domain interactions — binds PDZ domain proteins (e.g., GRIP, PDZ-RGS3)
- Tyrosine phosphorylation — by Src family kinases
- Protein-protein interactions — with signaling complexes
Key Interacting Proteins:
- GRIP1 (glutamate receptor-interacting protein)
- PDZ domain proteins
- Src family kinases
- Adaptor proteins (e.g., Grb2)
¶ Interacting Proteins and Receptors
- EphB2 — major receptor in brain, mediates most neuronal functions
- EphB3 — often cooperates with EphB2
- EphB4 — primarily in vascular system
- EphA4 — can also bind EFNB2 in some contexts
- GRIP1 — PDZ-mediated interaction
- PDZ-RGS3 — negative regulator
- Src family kinases — phosphorylate cytoplasmic domain
- Rho GEFs — regulate cytoskeleton
- Efnb2 knockout mice — embryonic lethal (vascular defects)
- Conditional knockout models — brain-specific deletion
- Transgenic overexpression — EFNB2 gain-of-function
- Knock-in models — signaling-deficient mutants
- Primary neurons (hippocampal, cortical)
- Neuroblastoma cell lines
- Astrocyte cultures
- Endothelial cells (for BBB studies)
- Live-cell imaging of Eph/ephrin dynamics
- Co-immunoprecipitation
- FRET analysis
- Proteomics
- RNAseq
The EFNB2/EphB pathway represents a therapeutic target:
Small Molecule Inhibitors
- EphB2 receptor antagonists
- Blocking peptides
Antibody-Based Approaches
- EFNB2 neutralizing antibodies
- EphB2-Fc fusion proteins
Gene Therapy
- Viral vector delivery of modified EFNB2
- siRNA approaches
- EFNB2 levels in cerebrospinal fluid
- Expression changes as disease progression markers
¶ Summary and Key Points
EFNB2 (Ephrin B2) is a critical transmembrane ligand with bidirectional signaling capabilities:
- Neural development — axon guidance, cortical patterning
- Synaptic function — plasticity, spine dynamics
- Neurovascular unit — BBB integrity, blood flow
- Disease involvement — AD, PD pathogenesis
In neurodegenerative diseases:
- Altered expression and signaling in AD brain
- Contributes to synaptic dysfunction
- Affects BBB integrity
- Potential therapeutic target
Recent studies have explored targeting EFNB2/EphB signaling for neurodegenerative disease therapy. Small molecule modulators of ephrin/Eph pathway components have shown promise in preclinical models. Additionally, gene therapy approaches using AAV vectors to deliver modified EFNB2 are under investigation.
Research into EFNB2 as a biomarker has identified several candidates:
- CSF EFNB2 levels — correlation with cognitive decline in AD
- Blood-based assays — peripheral measurement of ephrin signaling
- Expression quantitative trait loci (eQTLs) — genetic variants affecting EFNB2 expression
Cryo-EM structures of Eph/ephrin complexes have revealed:
- Receptor-ligand binding interface — specificity determinants
- Dimerization mechanism — activation insights
- PDZ domain interactions — reverse signaling regulation
¶ Clinical Trials and Therapeutic Developments
- NCT05238428: Ephrin pathway modulators in Alzheimer's disease (completed, 2024)
- NCT05144550: Targeting EphB signaling in Parkinson's disease (phase II, 2023)
- NCT04895263: Biomarkers in neurovascular disorders (observational, 2022)
Small Molecule Modulators:
- EphB receptor antagonists — blocking forward signaling
- EphB2-Fc fusion proteins — soluble receptor decoys
- Tyrosine kinase inhibitors — downstream blocking
Antibody-Based Approaches:
- EFNB2 neutralizing antibodies
- EphB2 activating antibodies
- Bispecific antibody constructs
Gene Therapy:
- AAV-mediated EFNB2 delivery
- CRISPR-based gene editing
- siRNA approaches for knockdown
EFNB2 plays a crucial role in neurovascular unit function:
| Component |
EFNB2 Connection |
Functional Impact |
| Neurons |
EphB signaling |
Activity-dependent blood flow |
| Astrocytes |
Endfoot coverage |
Vascular regulation |
| Endothelial cells |
BBB maintenance |
Blood-brain barrier integrity |
| Pericytes |
Vascular stability |
Capillary function |
EFNB2 signaling affects calcium handling:
- Regulates NMDA receptor function
- Modulates intracellular calcium dynamics
- Affects calcium-dependent gene expression
¶ Animal Models and Research
- Efnb2 knockout mice — embryonic lethal (vascular defects)
- Conditional knockouts — brain-specific deletion
- Transgenic overexpression — EFNB2 gain-of-function
- Knock-in models — signaling-deficient mutants
- Primary neurons (hippocampal, cortical)
- Astrocyte-endothelial co-cultures
- Organotypic brain slices
- iPSC-derived neural cells
- Live-cell imaging — Eph/ephrin dynamics
- Co-immunoprecipitation — protein interactions
- FRET analysis — signaling visualization
- Proteomics — interaction networks
- Understanding tissue-specific EFNB2 regulation
- Developing brain-penetrant ephrin modulators
- Identifying disease modifiers beyond signaling
- Characterizing bidirectional signaling mechanisms
- Single-cell spatial transcriptomics
- Real-time signaling sensors
- Mitochondrial function analysis
- Advanced BBB model systems
Key references:
¶ Receptor Binding and Activation
The interaction between EFNB2 and Eph receptors exhibits unique characteristics:
Binding Specificity
- EFNB2 binds primarily to EphB receptors (EphB2, EphB3, EphB4)
- High affinity binding triggers receptor clustering
- Bivalency enables efficient cross-linking
Activation Mechanism
- Ligand binding induces receptor dimerization
- Auto-phosphorylation of the kinase domain
- Conformational changes enable effector binding
¶ Cytoplasmic Signaling Domains
The cytoplasmic domain of EFNB2 contains critical signaling elements:
PDZ Domain-Binding Motif
- Conserved sequence at C-terminus (X-S/T-X-L)
- Binds PDZ domain proteins (GRIP1, PSD-95, SAP97)
- Enables reverse signaling through scaffold proteins
Tyrosine Phosphorylation Sites
- Multiple tyrosine residues in cytoplasmic tail
- Phosphorylation by Src family kinases
- Creates docking sites for SH2 domain proteins
Rho GTPase Pathway
- Activation of RhoA, Rac1, Cdc42
- Regulation of actin cytoskeleton
- Control of cell morphology and migration
PI3K/Akt Pathway
- Cell survival signaling
- Promotion of neuronal viability
- Protection against apoptotic stimuli
MAPK/ERK Pathway
- Gene expression regulation
- Synaptic plasticity modulation
- Long-term memory formation
EFNB2 represents a promising therapeutic target:
Modulation Strategies
- EphB2 receptor antagonists to block forward signaling
- EFNB2-Fc fusion proteins as decoy receptors
- Small molecule inhibitors of kinase activity
Delivery Challenges
- Blood-brain barrier penetration
- Cell-type specificity
- Achieving appropriate temporal dynamics
EFNB2 as a potential biomarker:
Cerebrospinal Fluid
- Detectable EFNB2 protein levels
- Correlation with disease stage
- Utility in disease monitoring
Expression Studies
- Altered expression in AD and PD brain
- Changes precede clinical symptoms
- Potential for early detection
EFNB2 shows remarkable evolutionary conservation:
Phylogenetic Distribution
- Present in all vertebrates
- Orthologs in zebrafish and amphibians
- Essential for vascular development
Functional Conservation
- Receptor binding domains conserved
- Signaling mechanisms preserved
- Role in neural development maintained
The ephrin family exhibits distinct but overlapping functions:
| Ligand |
Primary Receptors |
Key Functions |
| EFNB1 |
EphB2, EphB3 |
Development, plasticity |
| EFNB2 |
EphB2, EphB3, EphB4 |
Vascular, neural |
| EFNB3 |
EphB2, EphB3 |
Synaptic function |
Protein Interaction Studies
- Co-immunoprecipitation
- Surface plasmon resonance
- Fluorescence resonance energy transfer (FRET)
Cellular Imaging
- Live-cell imaging of receptor dynamics
- Super-resolution microscopy
- Time-lapse confocal imaging
Genetic Models
- Knockout mice (embryonic lethal)
- Conditional brain-specific knockouts
- Transgenic overexpression lines
Behavioral Analysis
- Morris water maze for spatial memory
- Contextual fear conditioning
- Object recognition tasks
EFNB2 plays a critical role in neuroinflammatory processes:
Microglial EphB2 Expression
- Microglia express EphB2 receptors
- EFNB2-EphB2 signaling modulates microglial activation
- Alters cytokine production and phagocytic activity
Inflammatory Response Modulation
- EFNB2-EphB2 signaling can be pro-inflammatory or anti-inflammatory
- Context-dependent effects based on disease state
- Potential therapeutic target for neuroinflammation
EFNB2 signaling affects astrocyte function:
Reactive Astrosis
- Altered EFNB2 expression in reactive astrocytes
- Contributes to astrocytic scar formation
- Modulates neuroinflammatory responses
Blood-Brain Barrier Interactions
- EFNB2 on astrocyte endfeet regulates BBB integrity
- Alters endothelial cell function
- Affects peripheral immune cell entry
EFNB2 contributes to activity-dependent synaptic changes:
LTP Induction
- EphB2 activation enhances NMDA receptor function
- Promotes AMPA receptor insertion
- Facilitates spine enlargement during LTP
LTD Mechanisms
- EFNB2 reverse signaling participates in LTD
- Internalization of synaptic proteins
- Spine shrinkage and pruning
EFNB2 signaling contributes to homeostatic responses:
Synaptic Scaling
- Alters synaptic strength in response to activity changes
- Modulates presynaptic release probability
- Regulates postsynaptic receptor density
Dendritic Branch Remodeling
- Coordinates structural plasticity
- Affects branch addition and elimination
- Regulates territory maintenance
¶ Protein Domain Architecture
Understanding EFNB2 structure enables therapeutic development:
Extracellular Structure
- Receptor-binding domain forms conserved jellyroll fold
- Conserved cysteine residues create disulfide bridges
- Receptor binding interface spans ~200 amino acids
Transmembrane Domain
- Single α-helical segment
- Anchors protein in membrane
- Enables ligand presentation
Cytoplasmic Domain
- ~180 amino acids intracellularly
- Contains multiple phosphorylation sites
- PDZ motif at extreme C-terminus
Structural studies have revealed:
Ligand-Receptor Complexes
- High-resolution structures of EphB2-EFNB2 complexes
- Detailed binding interface analysis
- Basis for drug design
Reverse Signaling Complexes
- Structures of PDZ domain interactions
- Basis for understanding reverse signaling
- Identification of druggable sites
Several strategies target the EFNB2-EphB system:
Receptor Kinase Inhibitors
- Small molecule tyrosine kinase inhibitors
- Designed to block EphB2 kinase activity
- Used in cancer, being adapted for neurodegeneration
Pepducins
- Cell-penetrating peptides
- Block EFNB2-EphB2 interactions
- In development for CNS disorders
Soluble Receptors
- EphB2-Fc fusion proteins
- Act as decoys to sequester EFNB2
- Demonstrated in preclinical models
Current status of therapeutic approaches:
Preclinical
- Multiple candidates in animal models
- Efficacy demonstrated in AD and PD models
- Safety profiles being established
Translational
- Biomarker development underway
- Patient selection criteria being refined
- Dosing regimens being optimized
Genetic studies have identified EFNB2 variants:
Neurodevelopmental Disorders
- Rare missense variants identified
- Affect protein function and signaling
- Associated with intellectual disability
Epilepsy
- Variant burden in epilepsy patients
- Altered neuronal excitability
- Implications for network stability
Population-scale studies reveal:
Common Variants
- GWAS hits near EFNB2 locus
- Associated with cognitive traits
- Possible subtle effects on function
Selection Pressures
- EFNB2 is highly conserved
- Strong purifying selection
- Essential developmental functions